- Home
- MCS vs MREO Comparison
MCS vs MREO Comparison
Compare MCS & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCS
- MREO
- Stock Information
- Founded
- MCS 1935
- MREO 2015
- Country
- MCS United States
- MREO United Kingdom
- Employees
- MCS N/A
- MREO N/A
- Industry
- MCS Movies/Entertainment
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- MCS Consumer Discretionary
- MREO Health Care
- Exchange
- MCS Nasdaq
- MREO Nasdaq
- Market Cap
- MCS 537.6M
- MREO 438.8M
- IPO Year
- MCS N/A
- MREO N/A
- Fundamental
- Price
- MCS $17.30
- MREO $1.66
- Analyst Decision
- MCS Strong Buy
- MREO Strong Buy
- Analyst Count
- MCS 3
- MREO 5
- Target Price
- MCS $25.00
- MREO $7.20
- AVG Volume (30 Days)
- MCS 183.1K
- MREO 3.6M
- Earning Date
- MCS 07-31-2025
- MREO 08-12-2025
- Dividend Yield
- MCS 1.63%
- MREO N/A
- EPS Growth
- MCS N/A
- MREO N/A
- EPS
- MCS N/A
- MREO N/A
- Revenue
- MCS $704,626,000.00
- MREO N/A
- Revenue This Year
- MCS $13.12
- MREO N/A
- Revenue Next Year
- MCS $4.22
- MREO $52.34
- P/E Ratio
- MCS N/A
- MREO N/A
- Revenue Growth
- MCS 3.81
- MREO N/A
- 52 Week Low
- MCS $10.73
- MREO $1.58
- 52 Week High
- MCS $23.16
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- MCS 51.82
- MREO 29.70
- Support Level
- MCS $16.60
- MREO $2.77
- Resistance Level
- MCS $17.64
- MREO $3.05
- Average True Range (ATR)
- MCS 0.53
- MREO 0.18
- MACD
- MCS 0.02
- MREO -0.06
- Stochastic Oscillator
- MCS 63.39
- MREO 9.76
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are movie theatres and Hotels and Resorts. The movie theatres segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio and others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).